# US 2013/0158101 A1 · Regulators of nfat and/or store-operated calcium entry

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158101 A1
- Document ID: US20130158101A1
- Status: Published application
- Kind: A1
- Application number: 13/761,444
- Filed: 2013-02-07
- Published: 2013-06-20
- Earliest claimed: 2009-10-08
- Assignees: Immune Disease Institute, Inc.
- Inventors: Anjana Rao; Patrick Hogan; Sonia Sharma
- Web page: https://patentgrep.com/patent/US20130158101A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12Y 306/01: in phosphorus-containing anhydrides (3.6.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of proteins involved in the calcineurin/NFAT axis.

## Claims

### Claim 1

A method of modulating NFAT activity in a subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the activity a protein and/or the expression of a gene identified in Table 4.

### Claim 2 (depends on 1)

The method of claim 1, wherein the modulation of NFAT activity comprises increasing the immune response in a subject in need thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subject is suffering from an immunodeficiency disorder selected from a group consisting of HIV (human immunodeficiency virus) and AIDS (acquired immunodeficiency syndrome), X-linked agammaglobulinemia, selective IgA deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, leukocyte adhesion defects, Bruton disease, kidney failure, and combined immunodeficiency disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is suffering from a cell proliferation disease or disorder.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cell proliferation disease or disorder is a neoplastic cell proliferation disorder.

### Claim 6 (depends on 4)

The method of claim 4, wherein the neoplastic cell proliferation disorder is a therapy resistant cancer, a metastasis or malignant cancer.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is suffering from a cardiovascular disorder.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cardiovascular disorders is cardiac hypertrophy, restenosis, atherosclerosis, or angiogenesis.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is suffering from a bone disease associated with excessive osteoclast formation and the excessive activity needs to be suppressed.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject is suffering from an angiogenic disease or disorder.

### Claim 11 (depends on 10)

The method of claim 10, wherein the angiogenesis disorder is associated with VEGF-induced and IL-1 induced gene expression.

### Claim 12 (depends on 10)

The method of claim 10, wherein the angiogenesis disorder is selected from a group consisting of cancer, age-related macular degeneration, diabetic retinopathy; rheumatoid arthritis; Alzheimer's disease; obesity and endometriosis.

### Claim 13 (depends on 1)

The method of claim 1, wherein the agent is a nucleic acid inhibitor which inhibits gene expression.

### Claim 14 (depends on 13)

The method of claim 13, wherein the nucleic acid inhibitor is an siRNA or shRNA.

### Claim 15

A method of modulating store-operated Ca2+ entry into a cell, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the activity of a protein and/or the expression of a gene identified in Table 4.

### Claim 16 (depends on 15)

The method of claim 15, wherein the agent is a nucleic acid inhibitor which inhibits gene expression.

### Claim 17

A method of treating and/or preventing hyperactivity or inappropriate immune response in a subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the activity a candidate protein and/or the expression of a gene identified in Table 4, wherein the gene is not calcineurin, calmodulin, Stim1 (stromal interaction molecule 1), Stim2 (stromal interaction molecule 2), Orai1 (calcium release-activated calcium modulator 1), KCNN4 (potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4) or dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2).

### Claim 18 (depends on 17)

The method of claim 17, wherein the hyperactivity or inappropriate immune response in a subject is associated with acute and chronic immune diseases selected from a group consisting of asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, rheumatoid arthritis, insulin-dependent diabetes, inflammatory bowel disease, autoimmune thyroiditis, hemolytic anemia, multiple sclerosis, transplant graft rejections and graft-versus-host disease.

### Claim 19 (depends on 17)

The method of claim 17, wherein the agent is a nucleic acid inhibitor which inhibits gene expression.

### Claim 20 (depends on 19)

The method of claim 19, wherein the nucleic acid inhibitor is an siRNA or shRNA.
